• Corpus ID: 246035594

Modeling interaction of Glioma cells and CAR T-cells considering multiple CAR T-cells bindings

@inproceedings{Li2022ModelingIO,
  title={Modeling interaction of Glioma cells and CAR T-cells considering multiple CAR T-cells bindings},
  author={Runpeng Li and Prativa Sahoo and Dongrui Wang and Qixuan Wang and Christine E. Brown and Russell C. Rockne and Hey-Young Cho},
  year={2022}
}
Chimeric antigen receptor (CAR) T-cell based immunotherapy has shown its potential in treating blood cancers, and its application to solid tumors is currently being extensively investigated. For glioma brain tumors, various CAR T-cell targets include IL13R 2, EGFRvIII, HER2, EphA2, GD2, B7-H3, and chlorotoxin. In this work, we are interested in developing a mathematical model of IL13R 2 targeting CAR T-cells for treating glioma. We focus on extending the work of Kuznetsov et al. (1994) by… 

Data driven model discovery and interpretation for CAR T-cell killing using sparse identification and latent variables

This work presents the first application of the sparse identification of non-linear dynamics (SINDy) algorithm to a real biological system in order to discover cell-cell interaction dynamics in in vitro experimental data, using chimeric antigen receptor (CAR) T-cells and patient-derived glioblastoma cells.

References

SHOWING 1-10 OF 26 REFERENCES

Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data

It is observed that CAR T-cell dose correlates inversely with the killing rate and correlates directly with the net rate of proliferation and exhaustion, and the exhaustion rate was observed to increase significantly with tumour growth rate and was dependent on level of antigen expression.

Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer.

CARTmath—A Mathematical Model of CAR-T Immunotherapy in Preclinical Studies of Hematological Cancers

A three-population mathematical model is developed to describe tumor response to CAR-T cell immunotherapy in immunodeficient mouse models, encompassing interactions between a non-solid tumor andCAR-T cells (effector and long-term memory), finding that therapy effectiveness mostly depends on specific parameters.

CAR T cell therapy: A new era for cancer treatment (Review).

An insight is presented into the advantages and the advances of CAR immunotherapy and the emerging discrepancy of CAR therapy over usual forms of therapy, such as chemotherapy and radiotherapy.

Mathematical model of Chimeric Anti-gene Receptor (CAR) T cell therapy with presence of cytokine

This paper reconstructs a mathematical model of therapy by CAR T cells for acute lymphoblastic leukemia (ALL) and applies method of Pontryagin's maximum principle for optimal control theory and simulates the clinical results by Matlab.

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

Recurrent multifocal glioblastoma patients received chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2) and regression of all intracranial and spinal tumors was observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid.

The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy

A mathematical model of T cell–tumour cell interactions is developed and it is demonstrated that expansion can be explained by immune reconstitution dynamics after LD and competition among T cells.

Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy

Treatment of epithelial cancers may be particularly challenging because of a paucity of target antigens expressed by carcinomas and not by important healthy tissues, and one strategy to overcome these negative regulators is to modulate expression of T-cell genes to enhance intrinsic T- cell function.

CAR-T cell Goes on a Mathematical Model

Hundreds of new clinical trials were recently launched using chimeric antigen receptor-bearing T cells (CAR-T cell) to expand treatment to diseases, including solid cancers, as well as on new strategies for managing dose administration protocols and toxicity to improve therapy outcomes.